---
News

Awakn Life Sciences Signs Drug Development Agreement With Catalent For Zydis® Technology (An Orally Disintegrating Tablet) To Conduct Feasibility Studies To Improve Differentiation Of Its MDMA Program

Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis® Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of its MDMA Program

TORONTO, CANADA, Sept, 12 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…

1 2 7

Sign Up for Newsletter

Awakn_logo_corp

MAIN OFFICE
18 Dukes Road,
London WC1H 9PY, United Kingdom

UK OFFICE
1 Regent Street, Bristol, BS8 4HW, United Kingdom

© 2021 Awakn Life Sciences Corp      |      Privacy Policy      |      Appropriate Use Policy

Back to top Arrow